首頁 > 市場調查報告書 > 製藥

臨床實驗

嗜中性白血球低下症市場規模、佔有率、成長分析（依治療類型、風險因子、藥物類別及地區分類）－2025-2032年產業預測

市場調查報告書

商品編碼

1854238

嗜中性白血球低下症市場規模、佔有率、成長分析（依治療類型、風險因子、藥物類別及地區分類）－2025-2032年產業預測

Febrile Neutropenia Market Size, Share, and Growth Analysis, By Treatment Type, By Risk Factors, By Drug Class, By Region - Industry Forecast 2025-2032

出版日期: 2025年10月22日 | 出版商:

SkyQuest | 英文 185 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球嗜中性白血球低下症市場預計在 2023 年達到 119 億美元，從 2024 年的 125.5 億美元成長到 2032 年的 192.7 億美元，在預測期（2025-2032 年）內以 5.5% 的複合年成長率。

發燒性嗜中性白血球低下症市場主要受全球癌症發生率上升的影響，加劇了化療相關嗜中性嗜中性白血球低下併發症的風險。化療和免疫抑制療法的日益普及推動了對有效預防措施的需求。此外，長效粒細胞集落刺激因子（G-CSF）療法的進展以及生物相似藥的核准正在改善治療的可及性，尤其是在已開發市場和新興市場。然而，仍有許多挑戰，例如生物相似藥的高成本，這阻礙了其在中低收入地區的應用。此外，長期使用G-CSF引發了人們對持續副作用的擔憂。對抗生素抗藥性的擔憂以及生物相似藥核准監管狀況的不確定性進一步加劇了市場格局的複雜性。

全球嗜中性白血球低下症市場促進因素

嗜中性白血球低下症症市場的主要促進因素是癌症發生率的上升和人口老化，老年人更容易罹患各種惡性腫瘤。隨著癌症治療，尤其是化療，變得更加積極和廣泛，嗜中性白血球低下症（一種以發燒和嗜中性白血球為特徵的嚴重併發症）的風險也在增加。這種日益成長的發病率推動了對有效預防療法和治療方案的需求，促進了藥物研發創新，並增加了醫療保健支出。此外，公眾意識的提高和診斷技術的進步也有助於嗜中性白血球低下症的早期發現和治療，進一步推動了市場成長。

全球嗜中性白血球低下症市場的限制因素

全球嗜中性白血球低下症症市場的主要限制因素之一是創新治療和支持性護理藥物研發及生產高成本。這種經濟負擔往往限制了病患的用藥可近性，尤其是在醫療資源有限的中低收入國家。此外，臨床試驗的複雜性和嚴格的監管核准流程會延緩新療法的上市，進一步阻礙市場成長。而且，醫療專業人員對嗜中性白血球低下症的認知和了解不足，會導致漏診和治療不足，加劇該市場面臨的挑戰。

全球嗜中性白血球低下症市場趨勢

由於生物相似藥在癌症支持治療中日益普及和應用，全球嗜中性白血球低下症症市場正經歷著變革性的變化。Filgrastim和Pegfilgrastim等生物相似藥的核准不斷增加，提高了治療的可近性，尤其是在新興市場，在這些市場，經濟有效的治療方案對於實現公平的癌症治療至關重要。這一趨勢促進了醫療服務提供者之間的良性競爭，最終將改善患者預後並降低醫療成本。隨著全球醫療體系適應這些創新，市場有望迎來顯著擴張，反映出人們普遍致力於改善癌症基本治療方法的可近性並提高患者的生活品質。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2024 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2024 年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2022-2024年收益年比比較

主要企業簡介

Amgen Inc.（USA）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
Viatris Inc.（USA）
Biocon Biologics Ltd（India）
Coherus BioSciences, Inc.（USA）
Kyowa Kirin Co., Ltd.（Japan）
Spectrum Pharmaceuticals, Inc.（USA）
Hanmi Pharmaceutical Co., Ltd.（South Korea）
BeyondSpring Inc.（USA）
G1 Therapeutics, Inc.（USA）
Partner Therapeutics, Inc.（USA）
Cellerant Therapeutics, Inc.（USA）
Fresenius Kabi（Germany）
Intas Pharmaceuticals Ltd.（India）
Gedeon Richter Plc.（Hungary）
Aurobindo Pharma Limited（India）
Amneal Pharmaceuticals, Inc.（USA）
Merck & Co., Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35I2453

Global Febrile Neutropenia Market size was valued at USD 11.9 billion in 2023 and is poised to grow from USD 12.55 billion in 2024 to USD 19.27 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The febrile neutropenia market is primarily influenced by the rising global incidence of cancer, which escalates the risk of neutropenic complications related to chemotherapy. The increasing use of chemotherapy and immunosuppressive therapies underscores a heightened demand for effective preventive measures. Furthermore, advancements in long-acting G-CSF therapies and regulatory approvals for biosimilars enhance treatment accessibility, particularly in developed and emerging markets. However, significant challenges persist, including the high costs associated with biosimilars that hinder availability in low- and middle-income regions. Additionally, limited awareness and late diagnoses contribute to hospitalizations at more severe stages, while chronic G-CSF use raises ongoing side effects concerns. The looming fear of antibiotic resistance and regulatory uncertainties regarding biosimilar approvals further complicate the market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Febrile Neutropenia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Febrile Neutropenia Market Segments Analysis

Global Febrile Neutropenia Market is segmented by Treatment Type, Risk Factors, Drug Class and region. Based on Treatment Type, the market is segmented into Prophylactic Treatment and Therapeutic Treatment. Based on Risk Factors, the market is segmented into Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia and Genetic Disorders. Based on Drug Class, the market is segmented into Antibiotics, Granulocyte Colony-Stimulating Factors, Antifungals and Antivirals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Febrile Neutropenia Market

A key market driver for the global febrile neutropenia market is the increasing prevalence of cancer and the growing aging population, which is more susceptible to various types of malignancies. As cancer treatments, particularly chemotherapy, become more aggressive and widespread, the risk of febrile neutropenia-a severe complication characterized by fever and low neutrophil counts-escalates. This rising incidence drives demand for effective prophylactic therapies and treatment options, fueling innovations in drug development and increasing healthcare expenditure. Additionally, heightened awareness and improved diagnostic techniques contribute to earlier detection and management of febrile neutropenia, further propelling market growth.

Restraints in the Global Febrile Neutropenia Market

One of the key market restraints for the global febrile neutropenia market is the high cost associated with the development and manufacture of innovative therapeutics and supportive care medications. This financial burden often limits accessibility for patients, particularly in low- and middle-income countries where healthcare resources are constrained. Additionally, the complexity of clinical trials and stringent regulatory approval processes can delay the introduction of new treatments, further inhibiting market growth. Furthermore, the lack of awareness and understanding of febrile neutropenia among healthcare providers may lead to underdiagnosis and under-treatment, compounding the challenges faced in this market.

Market Trends of the Global Febrile Neutropenia Market

The Global Febrile Neutropenia market is experiencing a transformative shift driven by the increased acceptance and integration of biosimilars in supportive cancer care. The growing approval of biosimilars like filgrastim and pegfilgrastim is enhancing treatment accessibility, particularly in developing markets, where cost-effective options are crucial for equitable cancer care. This trend fosters healthy competition among providers, ultimately leading to better patient outcomes and improved healthcare affordability. As healthcare systems globally adapt to these innovations, the market is poised for significant expansion, reflecting a broader commitment to increasing access to essential cancer care therapies and enhancing the quality of life for patients.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Febrile Neutropenia Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Prophylactic Treatment
Therapeutic Treatment

Global Febrile Neutropenia Market Size by Risk Factors & CAGR (2025-2032)

Market Overview
Chemotherapy-Induced Neutropenia
Transplant-Related Neutropenia
Genetic Disorders

Global Febrile Neutropenia Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Antibiotics
Granulocyte Colony-Stimulating Factors
Antifungals
Antivirals

Global Febrile Neutropenia Market Size & CAGR (2025-2032)

North America (Treatment Type, Risk Factors, Drug Class)
- US
- Canada
Europe (Treatment Type, Risk Factors, Drug Class)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Risk Factors, Drug Class)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Risk Factors, Drug Class)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Risk Factors, Drug Class)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon Biologics Ltd (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coherus BioSciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spectrum Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hanmi Pharmaceutical Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeyondSpring Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
G1 Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Partner Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellerant Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gedeon Richter Plc. (Hungary)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments